Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Crescent Biopharma, Inc.

NASDAQ: CBIO · Life Sciences · 8 alerts · CIK 1253689

Share price
$13.50Close, Nov 16
Market cap
$525M
Shares outstanding
38.9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Crescent Biopharma, Inc. filings on SEC EDGAR ↗

4:16 PM ET 8-K
Financial Results

Crescent Biopharma Financial Results

Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.

Counterparty
Kelun-Biotech

“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”

Joshua Brumm, chief executive officer of Crescent

“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”

Joshua Brumm, chief executive officer of Crescent
4:12 PM ET 10-Q
Financial Results

Crescent Biopharma Q3 2026 Results: Net Loss of $37.7M, Loss Widens

Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing its lead program, CR-001, and other product candidates. The company has a limited operating history, has never generated revenue from product sales, and anticipates continued losses for the foreseeable future as it advances its clinical trials.

Key figure
Net loss $37.7M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.